|
Malignant neoplasm of breast
|
0.300 |
GeneticVariation
|
disease |
UNIPROT |
|
|
|
|
Body Height
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Characterizing rare and low-frequency height-associated variants in the Japanese population.
|
31562340 |
2019 |
|
Non-Small Cell Lung Carcinoma
|
0.040 |
AlteredExpression
|
disease |
BEFREE |
SIGNIFICANCE OF THE STUDY: An elevated expression of SIX4 has been observed in colorectal cancer and nonsmall cell lung cancer.
|
31702057 |
2020 |
|
Non-Small Cell Lung Carcinoma
|
0.040 |
Biomarker
|
disease |
BEFREE |
We conclude that SIX4 plays an oncogenic role and may be potentially utilized as a diagnostic and therapeutic marker for NSCLC.
|
31266633 |
2019 |
|
Non-Small Cell Lung Carcinoma
|
0.040 |
AlteredExpression
|
disease |
BEFREE |
Overexpression of SIX4 partially reversed the role of miRNA-621 in the malignant progression of NSCLC.
|
31210312 |
2019 |
|
Non-Small Cell Lung Carcinoma
|
0.040 |
Biomarker
|
disease |
BEFREE |
Furthermore, the elevated expressions of SIX2, SIX4, and SIX6 predicted poor overall survival (OS) in NSCLC (SIX2: HR = 1.14, 95 % CI, 1.00-1.31; SIX4: HR = 1.39, 95 % CI, 1.16-1.66; SIX6: HR = 1.18, 95 % CI, 1.00-1.38) and poor relapse-free survival (RFS) in lung adenocarcinoma (ADC) (SIX2: HR = 1.42, 95 % CI, 1.14-1.77; SIX4: HR = 1.52, 95 % CI, 1.09-2.11; SIX6: HR = 1.25, 95 % CI, 1.01-1.56).
|
27821176 |
2016 |
|
Malignant Neoplasms
|
0.020 |
Biomarker
|
group |
BEFREE |
MiR-802 suppressed GBM cell proliferation, invasion, and EMT by directly targeting SIX4, which suggested important roles for miR-802/SIX4 axis in the GBM pathogenesis and its potential application in cancer therapy.
|
31702057 |
2020 |
|
Primary malignant neoplasm
|
0.020 |
Biomarker
|
group |
BEFREE |
MiR-802 suppressed GBM cell proliferation, invasion, and EMT by directly targeting SIX4, which suggested important roles for miR-802/SIX4 axis in the GBM pathogenesis and its potential application in cancer therapy.
|
31702057 |
2020 |
|
Colorectal Carcinoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
Collectively, we demonstrate that SIX4 is functional in regulating tumor angiogenesis and SIX4 might be used as anti-angiogenic therapy in CRC.
|
31301290 |
2019 |
|
Neoplasms
|
0.020 |
Biomarker
|
group |
BEFREE |
Overexpression of SIX4 enhances tumor growth and angiogenesis in vitro and in vivo, while knockdown of SIX4 inhibits tumor growth and angiogenesis.
|
31301290 |
2019 |
|
Malignant Neoplasms
|
0.020 |
AlteredExpression
|
group |
BEFREE |
SIX4 was upregulated in The Cancer Genome Atlas CRC cohort and other gene expression omnibus (GEO) cohorts.
|
28584719 |
2017 |
|
Colorectal Carcinoma
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
Moreover, SIX4 overexpression was related to unfavorable prognosis in CRC patients.
|
28584719 |
2017 |
|
Neoplasms
|
0.020 |
AlteredExpression
|
group |
BEFREE |
In addition, SIX4 expression significantly correlated with lymph node metastasis and advanced Tumor Node Metastasis (TNM) stages.
|
28584719 |
2017 |
|
Secondary malignant neoplasm of lymph node
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
In addition, SIX4 expression significantly correlated with lymph node metastasis and advanced Tumor Node Metastasis (TNM) stages.
|
28584719 |
2017 |
|
Primary malignant neoplasm
|
0.020 |
AlteredExpression
|
group |
BEFREE |
SIX4 was upregulated in The Cancer Genome Atlas CRC cohort and other gene expression omnibus (GEO) cohorts.
|
28584719 |
2017 |
|
Secondary malignant neoplasm of lymph node
|
0.020 |
Biomarker
|
disease |
BEFREE |
SIX4 and SIX6 were linked to the lymph node metastasis (LNM).
|
27821176 |
2016 |
|
Glioblastoma Multiforme
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
What is more, the SIX4 expression was negatively related to the miR-802 level in GBM tissues.
|
31702057 |
2020 |
|
Carcinogenesis
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
SIX4 acts as a master regulator of oncogenes that promotes tumorigenesis in non-small-cell lung cancer cells.
|
31266633 |
2019 |
|
Tumor Angiogenesis
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
Collectively, we demonstrate that SIX4 is functional in regulating tumor angiogenesis and SIX4 might be used as anti-angiogenic therapy in CRC.
|
31301290 |
2019 |
|
Progression of non-small cell lung cancer
|
0.010 |
Biomarker
|
disease |
BEFREE |
To clarify the role of microRNA-621 (miRNA-621)/SIX4 axis in regulating the malignant progression of non-small cell lung cancer (NSCLC) and the potential mechanism.
|
31210312 |
2019 |
|
Neoplasm Metastasis
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
SIX4 promotes metastasis via activation of the PI3K-AKT pathway in colorectal cancer.
|
28584719 |
2017 |
|
Tumor Cell Invasion
|
0.010 |
AlteredExpression
|
phenotype |
BEFREE |
SIX4 expression was silenced in two cell culture lines for invasion and wound healing assessment.
|
28584719 |
2017 |
|
Malignant neoplasm of colon and/or rectum
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
SIX4 promotes metastasis via activation of the PI3K-AKT pathway in colorectal cancer.
|
28584719 |
2017 |
|
Adenocarcinoma of lung (disorder)
|
0.010 |
Biomarker
|
disease |
BEFREE |
Furthermore, the elevated expressions of SIX2, SIX4, and SIX6 predicted poor overall survival (OS) in NSCLC (SIX2: HR = 1.14, 95 % CI, 1.00-1.31; SIX4: HR = 1.39, 95 % CI, 1.16-1.66; SIX6: HR = 1.18, 95 % CI, 1.00-1.38) and poor relapse-free survival (RFS) in lung adenocarcinoma (ADC) (SIX2: HR = 1.42, 95 % CI, 1.14-1.77; SIX4: HR = 1.52, 95 % CI, 1.09-2.11; SIX6: HR = 1.25, 95 % CI, 1.01-1.56).
|
27821176 |
2016 |